KEYNOTE-177
Pembrolizumab in MSI-H/dMMR Metastatic Colorectal Cancer
Patient / Population Intervention / Exposure Comparison Outcome
In 307 patients with untreated MSI-H/dMMR metastatic colorectal cancer, pembrolizumab improved progression-free survival compared with chemotherapy ± targeted agents.
N
307
Design
Open-label RCT
Endpoint
Progression-free survival
Relevance
2
ResultPFS 16.5 vs 8.2 months (HR 0.60). No OS benefit at primary readout (heavy crossover).
André T, et al. N Engl J Med. 2020;383(23):2207-2218. 10.1056/NEJMoa2017699
Discussion & critique
Established checkpoint inhibition as first-line standard in MSI-H/dMMR mCRC. Universal MMR/MSI testing at diagnosis is now non-negotiable.